Product Details
| Product Name:
Atuveciclib |
CAS No.:
1414943-88-6 |
| Purity:
98.80% |
Supply Ability:
10g |
| Release date:
2025/07/22 |
Product Introduction
Bioactivity
| Name | Atuveciclib |
| Description | Atuveciclib (BAY 1143572) is a potent and highly selective PTEFb/CDK9 inhibitor with an IC50 value of 13 nm for CDK9/CycT1 and a selectivity ratio of 100 for CDK2, with highly bioavailable and orally available advantages. |
| In vitro | Atuveciclib (BAY-1143572) exhibits a potent and highly selective inhibitory effect on PTEFb-kinase, specifically against PTEFb/CDK9, in the low nanomolar range, demonstrating at least 50-fold higher selectivity over other CDKs. The compound effectively inhibits the proliferation of seven AML cell lines, both with and without MLL rearrangements, evidenced by a median IC50 of 385 nM (ranging between 230-1100 nM), and it also triggers apoptosis[1]. Furthermore, Atuveciclib (BAY-1143572) differentiates itself by showing significant selectivity against a broad array of non-CDK kinases, coupled with wide-ranging antiproliferative effects across various tumor cell lines indicated by sub-micromolar IC50 values. Notably, it leads to the concentration-dependent inhibition of RNA polymerase II phosphorylation, subsequently diminishing MYC mRNA and protein levels[2]. |
| In vivo | Atuveciclib (BAY-1143572) significantly enhances its effectiveness when used with various chemotherapeutics across different solid tumor models. Additionally, it reduces MYC mRNA levels in the blood cells of treated rats, suggesting the potential of using MYC as a pharmacodynamic marker during clinical trials. When administered orally once daily, Atuveciclib demonstrates efficacy as a single agent, achieving partial or complete remission in most AML (acute myeloid leukemia) xenograft models in both mice and rats, proving its potency and tolerability at certain doses. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (258.11 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Cyclin dependent kinase | CDK9/CycT1 | CDK9 | CDK5/p35 | CDK3/cyclinE | CDK2/CyclinE | CDK1/CyclinB | CDK | BAY-1143572 | BAY1143572 | BAY 1143572 | Atuveciclib Racemate | Atuveciclib |
| Inhibitors Related | Ribociclib | Ro-3306 | Abemaciclib | Rafoxanide | AT7519 | Palbociclib monohydrochloride | CASIN | GW 441756 | Sodium Oxamate | Seliciclib | Abemaciclib methanesulfonate | Dinaciclib |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2250279-81-1
$0.00 / 50mg
-
CAS:2923012-24-0
$1510.00 / 100mg
-
CAS:1875036-74-0
$297.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$81.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-15 |
United States